BTIG analyst Robert Hazlett said that briefing documents for the advisory committee to discuss Amarin's (AMRN) Vascepa "appear generally benign" and largely supportive of the Omega-3 class, which he views as a positive for all Omega-3 participants, including Matinas BioPharma (MTNB), which is pre-screening patients for its additional upcoming head-to-head study of MAT9001 versus Vascepa in high triglyceride patients. He believes today's FDA advisory panel meeting should provide some clarity for the market opportunity of Omega-3s for cardiovascular risk reduction and keeps a Buy rating and $5 price target on Matinas shares.